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One of the most well-known methods, within data mining
framework, for discovering knowledge in multivariate data set is
clustering. The goal of clustering methods is to identify groups of
patients (i.e. clusters) such that patients in the same group are more
similar to each other than to patients in other groups.
Objective
Cluster Analysis
Hierarchical and partition clustering method around medoids based on
square root of Jensen–Shannon distance was applied to the multiple factor
analysis. This method is more robust to noise and outliers.
𝐷 𝑎, 𝑏 = 0.5 𝐾𝐿𝐷 𝑎,𝑚 + 0.5 𝐾𝐿𝐷(𝑏,𝑚)





The square root of Jensen-Shannon distance is a positive definite measure,
symmetric and triangular inequality. We added a small value to avoid zero in
the numerator and/or denominator of equation. Finally, the partitioning
around medoids (PAM) clustering algorithm was applied to cluster the
COPD data.
Classification of COPD is complicated by the heterogeneous and
multidimensional nature of the disease. In the past, application of
classification methods in this context had been developed by limited and
selected variables to define phenotypes with comparable results. However, in
this study we used multiple factor analysis (MFA), which is an extension of
principal component analysis (PCA), for reducing the complexity of high-
dimensional data.
Variables Reduction
In this study, we aim to identity distinct phenotypes of adults suffering from
chronic obstructive pulmonary disease (COPD). Clustering leads to better
understanding, management, future risks, prediction and treatment selection
optimization of different patient groups.
Conclusion
Reference
The best cluster number was found to be equal to 5. Those clusters
were identified as: mild COPD, Eosinophilic COPD, Atopic COPD,
COPD + Emphysema and neutrophilic COPD + Emphysema +
Systemic inflammation.
Table1. Part of Descriptive of Cluster Analysis (mean (std.error))
Application of this new cluster approach allowed to identify five
groups within stable COPD patients based on huge clinical variables
while accounting for noise and outlier. Derived results can be used to
predict outcomes of patients with COPD and to aid in development
of personalized therapy.
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+ neutrophilic + COPD
Variable n=68 n=18 n=4 n=61 n=23
Demographic
Age(year) 63.18(9.38) 62.28(9.14) 65(9.20) 66.06(9.14) 64.83(10.18)
Sex (Female) 40% (27) 61%(11) 25%(1) 59%(36) 22%(5)
Cigarette Packs (year) 40.48(29.52) 37.34(18.53) 60.25(46.08) 40.18(28.88) 37.18(18.01)
Smoking Duration 
(years)
39.30(13.51) 40.94(13.76) 43.5(6.56) 41.67(12.55) 41.54(14.02)
Pulmonary Function
FEV1Predict (%) 66.97(14.24) 47.39(10.15) 47.5(17.41) 48.69(13.79) 39.69(14.79)
CVF post (%) 89.94(16.06) 72.44(15.83) 65.75(21.93) 78.06(16.56) 65.95(15.44)
DEM 25/75 (%) 32.84(12.95) 26.87(12.33) 18.33(4.04) 21.65(9.69) 16.07(7.49)
VR/CPT (%) 52.83(9.25) 58.79(10.18) 69.67(2.08) 61.80(6.82) 63.36(8.89)
DLCO/VR (%) 74.98(21.49) 76.22(11.28) 92(19.67) 63.27(20.68) 69.43(26.80)
sGaw 0.65(0.33) 0.52(0.26) 0.35(0.08) 0.45(0.20) 0.35(0.19)
CRF PL (%) 145.78(35.29) 165.0(36.14) 150.67(30.24) 167.37(30.47) 165.78(39.35)
Treatment
β2-mimetic (Y/N) 0.28%(19) 78%(0.43) 0(0) 85%(52) 73%(17)
LABA-LAMA (Y/N) 47%(32) 94%(17) 50%(2) 97%(59) 100%(23)
SABA (Y/N) 18%(12) 56%(10) 50%(2) 59%(36) 39%(9)
Blood
Leuco 8.24(2.26) 8.59(1.72) 9.67(2.07) 7.21(1.81) 11.60(3.25)
Neutrophils (%) 58.25(7.94) 56.89(8.87) 59.45(9.06) 60.97(8.56) 75.66(11.0)
Lymphocyte(%) 30.33(7.93) 29.56(7.38) 32.72(6.95) 28.54(8.41) 15.83(7.69)
Mononucleosis (%) 8.66(2.30) 8.59(3.22) 5.87(1.80) 8.01(2.01) 6.56(3.11)
Eosinophils 2.26(1.67) 4.42(2.43) 1.95(1.56) 2.05(1.24) 1.66(1.46)
Basopenia (%) 0.49(0.28) 0.58(0.26) 0.27(0.09) 0.45(0.26) 0.29(0.17)
Fibrinogen (mg/l) 3.41(0.73) 3.63(0.66) 3.25(0.43) 3.51(0.79) 4.36(1.14)
CRP (mg/L) 4.57(6.19) 3.58(2.92) 4.57(3.37) 6.29(10.31) 24.99(36.83)
Atopy
IgE 108.18(213.52) 869.12(1402.68) 417.25(284.6) 328.31(882.54) 234.19(284.57)
DTP 0.08(0.48) 0.23(0.64) 7.07(9.04) 0.58(2.07) 0.02(0.11)
Sputum
FeNO (ppb) 20.22(18.65) 32.44(24.99) 26(16.75) 16.60(11.44) 22.23(13.10)
Cellular Account 2.75(4.82) 3.31(2.63) 6.59(2.58) 4.16(5.04) 29.94(41.17)
Macro 18.29(14.15) 22.37(13.55) 41.2 12.86(11.39) 5.78(6.39)
Lymphocyte 1.76(2.34) 5.7(16.65) 6.6 1.28(1.40) 0.96(2.08)
Neutrophils 72.14(18.28) 26.64(16.18) 48.8 78.95(13.84) 84.54(16.43)
Eosinophils 2.57(4.24) 26.72(28.72) 2.8 2.9(4.13) 6.33(11.54)
Epithelial 5.08(60.) 18.56(15.14) 0.6 4.01(3.94) 2.38(4.54)
Result
